#USA #Los Angeles #Neuroscience #Spinogenix #Joseph T. Coyle

Transformative Appointment in Neuroscience

Spinogenix, Inc., a pioneering clinical-stage biopharmaceutical firm, has added Professor Joseph T. Coyle, MD, who is a highly esteemed figure in the fields of psychiatry and neuroscience, to its Scientific Advisory Board (SAB). This strategic appointment promises to bolster the company's efforts in the clinical development of tazbentetol, a groundbreaking therapeutic agent that holds the potential to rejuvenate synaptic functions crucial for improving quality of life for patients suffering from neurodegenerative and neuropsychiatric disorders.

The announcement, made on July 2, 2026, underscores Spinogenix's commitment to advancing innovative solutions in the treatment of serious brain diseases, notably schizophrenia. Dr. Stella Sarraf, the company's CEO and Founder, expressed substantial enthusiasm regarding Prof. Coyle's involvement at this pivotal moment in the therapeutic journey of tazbentetol. Dr. Sarraf stated, "We are thrilled to welcome Prof. Coyle to Spinogenix's Scientific Advisory Board at this important stage in the development of tazbentetol. Prof. Coyle's pioneering work in neuropsychiatric research has shaped the current understanding of schizophrenia and other brain disorders. His expertise, particularly in advancing EEG biomarkers and translating neuroscience discoveries into clinical development, will be instrumental as we advance our schizophrenia program."

Prof. Coyle brings over four decades of research experience focused on the complexities of brain function and the intricacies of neuropsychiatric diseases. Renowned for his expertise in developmental neurobiology, glutamatergic pathways, and psychopharmacology, he has a prolific academic presence, having authored over 500 scientific papers and earned the distinction of being one of the most cited researchers in neuroscience worldwide.

During his tenure, Prof. Coyle has held several prestigious leadership roles including Chairman of the Department of Psychiatry at Harvard Medical School, President of the Society for Neuroscience, and President of the American College of Neuropsychopharmacology. He is also a member of the National Academy of Medicine and a Fellow of the American Academy of Arts and Sciences, proving his influence and continued commitment to furthering medical science. His groundbreaking research, consistently funded by the National Institutes of Health (NIH) for more than 30 years, has garnered over 87,000 citations, further reflecting his impact in the field.

In response to his new role at Spinogenix, Prof. Coyle shared, "Schizophrenia remains a highly complex neuropsychiatric disorder, highlighting the need for therapies that address its underlying biology. I have been particularly impressed by Spinogenix's novel synaptic regenerative approach to treating neurological conditions, as well as the company's commitment to integrating EEG into the clinical development of tazbentetol. I look forward to supporting the team as it continues developing this essential program."

Innovating Treatments for Unmet Needs

At a time when the pharmaceutical landscape for treating neurodegenerative and neuropsychiatric illnesses is rapidly evolving, Spinogenix aims to stand at the forefront by introducing transformative therapies rather than merely managing symptoms. Current treatment options predominantly focus on slowing disease progression or alleviating symptoms, leaving immense gaps in patient care. Spinogenix seeks to transcend these limitations with first-in-class therapies that regenerate synapses and address the root causes of these conditions.

The company is developing two significant therapeutic agents: Tazbentetol (formerly SPG302) is designed to stimulate the creation of new glutamatergic synapses, potentially restoring various cognitive, motor, and functional capabilities for patients with conditions such as ALS, Alzheimer's disease, and schizophrenia. The other, SPG601, targets synaptic dysfunction specifically in Fragile X Syndrome (FXS), aiming to correct symptoms that stem from synaptic abnormalities. Notably, Spinogenix has earned Orphan Drug designations for tazbentetol and SPG601 from both the FDA and EMA, recognizing the urgent need for effective treatments in these challenging areas.

As Spinogenix strides forward, the inclusion of Professor Joseph T. Coyle on their advisory board marks a significant step towards harnessing the collective knowledge and expertise in neuroscience to embark on a journey of redefining treatment methodologies that could greatly enhance the therapeutic landscape for millions affected by these debilitating conditions.

For further information about Spinogenix and their pioneering work, please visit www.spinogenix.com or follow them on LinkedIn.